William Ju, M.D.
President, CEO & Member, Board of Directors
Dr. Ju is a board-certified dermatologist who has 17 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. Prior to joining Follica, Dr. Ju was chief operating officer at PTC Therapeutics, where he played an important role in successfully leading and building the company including helping PTC triple in size, complete a $50 million Series E round, and enter into a partnership with Genzyme worth over $400 million. Prior to PTC, he held executive positions at Pharmacia Corporation and Merck Research Laboratories in a broad spectrum of product development functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the registration team for CRIXIVAN®. Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, he was a senior staff fellow in basic research in the Laboratory of Cellular Oncology and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. Dr. Ju obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.
Mary Osbakken, M.D., Ph.D
Shikha P. Barman, Ph.D.
Dr. Barman has over 16 years of experience in the translation of concepts into products in areas of drug delivery, pharmaceutical development and tissue engineering. Her expertise is in the design of cell-targeted delivery systems, customized to permeate molecular barriers such as the skin, corneal, and blood-brain barriers. She has contributed to approximately 25 U.S. Patents/PCTs, 65 publications and 3 book chapters. As senior director at Inotek Pharmaceuticals she coordinated cross-functional project teams for IND submissions for Phase I/II trials. At Sontra Medical Corporation she was responsible for all pharmaceutics and vaccine development in CMC and drug products to deliver vaccines and drugs epidermally. As head of gene delivery at Zycos, Inc., she led efforts to develop cell-targeted delivery systems for DNA therapeutics to treat HPV and cancer. As team leader at Focal, Inc, she developed delivery systems, hemostats, wound-healing tissue engineered constructs and tissue sealants. Dr. Barman has a Ph.D in Polymer Science and in Plastics Engineering from University of Massachusetts, a M.S. in Polymers from University of Massachusetts, and B.S. / M.S. in Chemistry from Auburn University.
Scott C. Kellogg
VP and Head of Operations
Mr. Kellogg has worked in the medical technology industry for over 17 years and is currently the Vice President and Head of Operations at Follica, Inc. Prior to joining Follica, Mr. Kellogg was an integral member of the founding teams at Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Development, Vice President of R&D, and Director of Engineering, respectively. In all of these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. These technologies included surgical modalities, transdermal analyte detection, transdermal drug delivery, and neurostimulation. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc. Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on multiple domestic and international patents.
Stephen Prouty, Ph.D.
VP & Head of Research
Dr. Stephen Prouty joined Follica in May, 2006. As Vice President and Head of Research, Dr. Prouty oversees Follica's preclinical and human proof-of-concept clinical research programs. Prior to joining Follica, Dr. Prouty oversaw diverse research programs at Johnson and Johnson as a Staff Scientist for 4 years and a Principal Scientist for 9 years. While at the Skin Biology Research Center of Johnson & Johnson Consumer Products WorldWide, Dr. Prouty worked with Dr. Kurt Stenn on numerous dermatology-focused programs. Dr. Prouty's research resulted in the cloning and characterization of the gene for human stearoyl-CoA desaturase, as well as the discovery of novel enzymatic reactions for other members of the desaturase gene family in sebaceous glands, a novel regulator of acne. Dr. Prouty then joined J&J's Enterology Team where he developed and managed drug and biomarker discovery projects for diseases of the gastrointestinal tract, including Crohn's disease, ulcerative colitis, and irritable bowel syndrome. Dr. Prouty obtained his Ph.D. in Anatomy/Neurobiology from Medical College of Pennsylvania and completed his postdoctoral training at Yale University School of Medicine, where he was awarded an American Cancer Society Fellowship.